Skip to main content

Table 4 Studies included in the pooled analysis

From: Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

Study [ref.] n. ECOG PS (n.) Basal CA19.9 (n.) median PFS (95 % CI) (months) median OS (95 % CI) (months) RR (%)
Present study 174 0: 106
1: 52
2: 16
<157 U/ml: 71
≥157 U/ml: 83
NR: 20
3.0 (2.7-3.4) 6.6 (5.1-8.1) 3.4
He, 2014 [13] 37 0-1: 29
2: 8
normal: 9
elevated: 28
3.1 (2.3-3.6) NR 21.6
Bridgewater, 2013 [14] 63 NR NR 4.0 (3.3-5.6) 8.1 (5.3-11.4) NR
Fiteni, 2014 [15] 16 NR NR 4.0 (2.6-5.5) 5.3 (4.1-6.6) NR
Brieau, 2015 [16] 196 0-1: 117
2–3: 56
≤400 U/ml: 81
>400 U/ml: 49
3.2 (2.8-4.0) 6.7 (5.6-7.8) 11.8
Guion-Dusserre, 2015 [17] 13 0: 3
1: 8
2: 2
median: 73 U/ml [range: 2–4472] 8 (7–16) 20 (8–48) 38.4
  1. Abbreviations: ref reference number, n number, ECOG PS Eastern Cooperative Oncology Group performance status, PFS progression-free survival, OS overall survival, CI confidence interval, RR response, rate, NR not reported